SCHEMBL2914947

SCHEMBL2914947

O=S(=O)(O)c1sc(Cl)cc1Br

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.41
CCR4 P51679 1/20 0.40
CCKBR P32239 1/20 0.39
KMT2A Q03164 1/20 0.37
GSK3B P49841 2/20 0.37
KDM4E B2RXH2 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
GPR35 Q9HC97 1/20 0.32
CDK1 P06493 1/20 0.31
CCNB1 P14635 1/20 0.31
CCNA2 P20248 1/20 0.31
CCND1 P24385 1/20 0.31
CDK2 P24941 1/20 0.31
CDK7 P50613 1/20 0.31
CCNH P51946 1/20 0.31
CCNA1 P78396 1/20 0.31
CDK6 Q00534 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27779746 0.98 DAO (0.39) DAOCCR4CCKBRKMT2AGSK3B
SCHEMBL1548108 0.83 CCR4 (0.41) DAOCCR4CCKBRKMT2AL3MBTL1
SCHEMBL390902 0.81 CCR4 (0.40) DAOCCR4CCKBRKMT2AGSK3B
SCHEMBL18701652 0.78 MCL1 (0.41) DAOGSK3BHPGDPKM
Hydrochloric Acid SCHEMBL27989877 0.77 OPRD1 (0.45) GSK3BOPRD1
SCHEMBL11349523 0.76 DAO (0.57) DAOKMT2AGSK3BKDM4EMAPT
SCHEMBL5183091 0.75 ALDH1A1 (0.38) DAOKMT2AKDM4EMAPTHPGD
SCHEMBL18701587 0.75 MCL1 (0.33) DAOMAPK1HTTRAB9APKM
SCHEMBL6847201 0.74 CCR4 (0.43) DAOCCR4CCKBRKMT2ATDP1
Potassium Ion SCHEMBL11502397 0.73 DAO (0.40) DAOKMT2AGSK3BKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101370779-B Cyclohexyl sulfonamide derivatives having H3 receptor activity HOFFMANN LA ROCHE 2011-07-20 CN claimed
CN-1972918-B Pyrimidine derivatives HOFFMANN LA ROCHE 2010-10-13 CN claimed
EP-1979322-B1 CYCLOHEXYL SULFONAMIDE DERIVATIVES HAVING H3 RECEPTOR ACTIVITY HOFFMANN LA ROCHE (CH) 2010-09-01 EP claimed
US-7569562-B2 N-substituted heterocyclic sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2009-08-04 US claimed
US-7507733-B2 11b-HSD1 inhibitors for the treatment of diabetes HOFFMANN-LA ROCHE INC. (US) 2009-03-24 US claimed
CN-101370779-A Cyclohexyl sulfonamide derivatives having H3 receptor activity HOFFMANN LA ROCHE (CH) 2009-02-18 CN claimed
EP-1979322-A1 CYCLOHEXYL SULFONAMIDE DERIVATIVES HAVING H3 RECEPTOR ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2008-10-15 EP claimed
EP-1838701-A1 N-SUBSTITUTED HETEROCYCLIC SULFONAMIDES Elan Pharmaceuticals Inc. (US) 2007-10-03 EP claimed
WO-2007082840-A1 CYCLOHEXYL SULFONAMIDE DERIVATIVES HAVING H3 RECEPTOR ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2007-07-26 WO claimed
CN-1972918-A Pyrimidine derivatives HOFFMANN LA ROCHE (CH) 2007-05-30 CN claimed
US-20060270657-A1 N-substituted heterocyclic sulfonamides ELAN PHARMACEUTICALS, INC. 2006-11-30 US claimed
WO-2006078753-A1 N-SUBSTITUTED HETEROCYCLIC SULFONAMIDES ELAN PHARMACEUTICALS, INC. (US) 2006-07-27 WO claimed
WO-2006000371-A2 PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2006-01-05 WO claimed
US-20050288308-A1 11B-HSD1 inhibitors for the treatment of diabetes F. HOFFMANN-LA ROCHE AG (CH) 2005-12-29 US claimed
EP-1455777-A1 GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS SMITHKLINE BEECHAM PLC (GB) 2004-09-15 EP claimed
EP-0946539-B1 SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS SMITHKLINE BEECHAM PLC (GB) 2003-08-13 EP claimed
WO-2003055478-A1 GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS SMITHKLINE BEECHAM P.L.C. (GB) 2003-07-10 WO claimed
US-20030069233-A1 Sulphonamide derivatives, process for their preparation, and their use as medicaments SMITHKLINE BEECHAM P.L.C. 2003-04-10 US claimed
EP-0946539-A1 SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS SMITHKLINE BEECHAM PLC (GB) 1999-10-06 EP claimed
WO-1998027081-A1 SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS SMITHKLINE BEECHAM PLC (GB) 1998-06-25 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069233-A1 Sulphonamide derivatives, process for their preparation, and their use as medicaments TPMT, MPST, STS DAO 1215/4885CCR4 4246/4885CCKBR 3589/4885
US-20050288308-A1 11B-HSD1 inhibitors for the treatment of diabetes HSD11B1, HSD17B1, HSD3B1 DAO 3594/4885CCR4 3452/4885CCKBR 1729/4885
US-20060270657-A1 N-substituted heterocyclic sulfonamides SULT2A1, PSEN1, PSEN2 DAO 2174/4885CCR4 4353/4885CCKBR 566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.